Stocks to sell

Nio (NYSE:NIO) has had one of the most incredible turnarounds in recent memory. The company’s initial public offering (IPO) was priced at $6 per share, and NIO stock stayed in the single digits following the IPO. Source: Sundry Photography / Shutterstock.com While Nio made a decent case about being able to beat Tesla (NASDAQ:TSLA) in
0 Comments
With meme stocks starting to tumble and Wall Street becoming much more skeptical about Clover Health (NASDAQ:CLOV), the outlook of CLOV stock has deteriorated meaningfully in recent weeks. Source: Shutterstock Meanwhile, Clover’s claims to be a high-tech disruptor are questionable, and the company continues to face Securites and Exchange Commission and Department of Justice probes,
0 Comments
The debate around cryptocurrency is always hot. Opinions are binary between haters and absolute lovers. But there is a giant portion of the population apathetic about the whole thing. Those are the future upside feeders to Coinbase (NASDAQ:COIN) and COIN stock. Source: Primakov / Shutterstock.com Many of my family members are in that group. They
0 Comments
With the stock-trading paradigm supposedly having shifted because of the novel coronavirus, fuel-cell electric vehicle (FCEV) specialist Plug Power (NASDAQ:PLUG)  looks awfully enticing. From its peak 2021 closing price of $73.18, PLUG stock is now down more than 60%. Of course, in this day and age of social media, such a decline represents about as
0 Comments
Any time I write about meme stocks, I like to distinguish between trading and investing. I have no idea where AMC Entertainment (NYSE:AMC) will trade next week or next month. If you are YOLOing on AMC stock the same way you’s bet on a horse at the Kentucky Derby, this story is not for you.
0 Comments
Given Organon & Co’s (NYSE:OGN) low growth, its sizeable competition, its lack of concrete positive catalysts, and the fact that its management plans to institute an average dividend in the future, I urge investors to avoid OGN stock for now. Source: Shutterstock Moreover, although Organon says that it’s looking to make acquisitions, its relatively low
0 Comments
MindMed (NASDAQ:MNMD) is a neuro-pharmaceutical company that specializes in psychedelic medicine. It discovers, develops and deploys these products to improve health, promote wellness and alleviate suffering. MNMD stock spiked after its initial public offering (IPO) in April, but has cooled since. Source: Shutterstock Is this a buying opportunity, or should investors steer clear of the stock? If
0 Comments